|
|
Line 17: |
Line 17: |
| *[http://online.wsj.com/article/SB123275818015611957.html?mod=loomia&loomia_si=t0:a16:g2:r2:c0.130796:b0 The North American Spine Society now requires its members to disclose all ties to medical device companies - including dollar amounts. Two weeks ago we told you about a University of Wisconsin researcher who raked in more than $19 million over five years from spinal device maker Medtronic. After coming under fire from lawmakers, the NASS made its disclosure policy dramatically stricter. The Wisconsin researcher had only been required to report earning "more than $20,000" in donations from medical companies. (Wall Street Journal)] | | *[http://online.wsj.com/article/SB123275818015611957.html?mod=loomia&loomia_si=t0:a16:g2:r2:c0.130796:b0 The North American Spine Society now requires its members to disclose all ties to medical device companies - including dollar amounts. Two weeks ago we told you about a University of Wisconsin researcher who raked in more than $19 million over five years from spinal device maker Medtronic. After coming under fire from lawmakers, the NASS made its disclosure policy dramatically stricter. The Wisconsin researcher had only been required to report earning "more than $20,000" in donations from medical companies. (Wall Street Journal)] |
|
| |
|
| '''January 26, 2009 By Michael W Tempelhof, MD [mailto:tempe004@mc.duke.edu]''' | | '''January 26, 2009: Measuring Fractional Flow Reserve During PCI Improves 1-Year Outcomes''' |
| | | *[[Measuring Fractional Flow Reserve During PCI Improves 1-Year Outcomes|Percutaneous coronary intervention (PCI) for treatment of NSTEMI and/or STEMI from ischemia has been associated with improvements in short-term and long-term clinical outcomes. However, in ischemic patients with multiple vessel disease, determination of which lesion is the culprit stentoic lesion requiring intervention is often difficult.]] |
| '''Measuring Fractional Flow Reserve During PCI Improves 1-Year Outcomes.'''
| |
| | |
| ''Percutaneous coronary intervention (PCI) for treatment of NSTEMI and/or STEMI from ischemia has been associated with improvements in short-term and long-term clinical outcomes. However, in ischemic patients with multiple vessel disease, determination of which lesion is the culprit stentoic lesion requiring intervention is often difficult.
| |
| -Fractional Flow Reserve (FFR): is the ratio of maximal blood flow in a stenotic vessel to normal maximal flow.''
| |
| | |
| STUDY OBJECTIVE:
| |
| To investigate whether FFR-guided PCI would be associated with better outcomes (rates of major adverse cardiac events (MACE) at 1 year, death, MI, or repeat revascularization at 1 year) vs. routine angiography-guided PCI in ischemic patients with multivessel disease.
| |
| | |
| STUDY DESIGN and METHODS:
| |
| 1005 Patients with stenoses of >50% in at least two of the three major coronary arteries where randomized to either routine PCI, or FFR-guided PCI, where FFR was measured in all significant stenoses, with stenting in lesions with an FFR ≤0.8.
| |
| | |
| RESULTS:
| |
| Rates of MACE at 1 year was significantly lower in the FFR arm compared with the routine-PCI arm (13.2% vs. 18.3%, p = 0.02). The incidence of death (1.8% vs. 3.0%, p = 0.19), myocardial infarction (MI) (5.7% vs. 8.7%, p = 0.07), and coronary artery bypass grafting or revascularization at year (6.5% vs. 9.5%, p = 0.08) was similar between both arms.
| |
| | |
| Mean procedure time was similar between the two study arms 70 minutes.
| |
| Quantity of contrast dye utilized was significantly lower in the FFR arm, 272ml vs. 302 ml for standard PCI arm. The number of patients who were angina free at 1 year was also similar between the two arms (81% vs. 78%, p = 0.2). As measured by the EuroQOL-5D, the quality of life scores were similar between the two arms(p = 0.65).
| |
| | |
| CONCLUSIONS:
| |
| The FAME trial results indicate that FFR-guided PCI is associated with a significantly lower incidence of MACE at year compared with routine angiography-guided PCI in ischemic patients with multivessel disease.
| |
| FFR-guided PCI had a favorable cost-benefit ratio, similar procedural times to standard PCI and exposed patients to less contrast dye.
| |
| | |
| Tonino PA, De Bruyne B, Pijls NH, et al., on behalf of the FAME Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.
| |
| | |
| ==Source==
| |
| N Engl J Med. 2009 Jan 15;360(3):213-24.
| |
| | |
| [[category:news]]
| |
| [[Category: Cardiovascular interventions News]]
| |
|
| |
|
| '''January 23, 2009: Citing Costs, Younger Americans Skipping Meds''' | | '''January 23, 2009: Citing Costs, Younger Americans Skipping Meds''' |
January 26, 2009: Larry Husten, the former editor of TheHeart.Org, will serve as WikiDoc's first Director of Medical Journalism
January 26, 2009: FDA Announces Ongoing Safety Review of Clopidogrel
January 26, 2009: Danish Researchers Recommend Avoiding NSAIDs in HF
- NSAIDs are associated with significant increases in death and cardiovascular morbidity, according to a large, new registry study from Denmark in the Archives of Internal Medicine. Danish researchers found dose-dependent elevated risk levels for death and risk of hospitalization with use of rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs. They conclude that “patients with HF should, if possible, avoid using any NSAIDs at any dosage for most NSAIDS and at high dosages for ibuprofen and naproxen.” Dr. Steven Nissen agrees with the recommendation of the researchers but fully acknowledges the limitations of this type of research. He told CardioBrief: “Like all observational studies, this one has important weaknesses. There are many known and unknown confounders for which adjustment is not possible. All NSAIDs increase sodium retention and these drugs have long been associated with increased risk of heart failure. With regard to the effects on MI and mortality, the results suggest a class effect, but this can only be verified by a well-designed, prospective randomized trial. We are conducting such as study, the PRECISION trial in 20,000 patients using three of these drugs, naproxen, ibuprofen, and celecoxib. Until the results are available, prudent practitioners should use NSAIDs in high risk patients only when absolutely necessary and should always use the lowest effective dosage for the least duration possible.”(CardioBrief)
January 26, 2009: Innovative stent company seeks emergency intervention
January 26, 2009: Evidence-Based Treatment for HF Sees Improvements
January 26, 2009: Follow-Up: Surgeons Adopting Strict Rules on Payments
January 26, 2009: Measuring Fractional Flow Reserve During PCI Improves 1-Year Outcomes
January 23, 2009: Citing Costs, Younger Americans Skipping Meds
January 23, 2009: Women with Heart Problems Often Left Waiting
January 23, 2009: 4,000-Person Drug Trial Scrapped After Sponsor Declares Bankruptcy
January 23, 2009: MA State Ethics Law Scuttles Plans for Medical Meeting
January 22, 2009: Gifts to Doctors Must Be Disclosed
January 22, 2009: Stroke Survivors with AF Have Greater Risk of Death
January 22, 2009: Women Make Better Heart Care Doctors?
January 22, 2009: American Journal of Clinical Nutrition
January 21, 2009: Pictures of a Bleeding Heart
January 21, 2009: More Doctors E-Mailing It In
January 21, 2009: Problems Pumping Iron? Maybe You’ve Got a Problem Pumping Blood
January 21, 2009: Bill Gates, Others Pledge $630 Million to End Polio
January 20, 2009: With a New President, a New Worry
January 20, 2009: First Time Heart Attacks Not as Severe
January 20, 2009: The “Sure Thing” Gene
January 20, 2009: Men Better at Resisting Temptation
January 20, 2009: Drug-Resistant Staph Infections Rising in Kids
January 16, 2009: Brian Blank has joined WikiDoc as its inaugural Scholar in Medical Journalism
January 16, 2009: Popular Health Risk Tools Don’t Find Heart Disease
January 16, 2009: Heparin-Induced Antibodies Point To Thrombosis Risk
January 16, 2009: Superbugs Vs. Cancer Drugs
January 16, 2009: Senator: Schools Failing to Regulate Medical Conflicts of Interest
January 16, 2009: Coffee Can Reduce Alzheimer’s, Cause Hallucinations
January 6, 2009: Cytochrome P450 2C19 polymorphism linked to poor outcomes for young MI patients treated with clopidogrel
- Patients who had CYP2C19*2 genetic variant in the CYP2C19 gene and were treated with clopidogrel after a myocardial infarction (MI) demonstrated worse cardiovascular outcomes than patients with a normal copy of the cytochrome P450 2C19 encoding gene, according to a study published in the Lancet. The study population was composed of 259 patients, all under the age of 45, who received clopidogrel treatments for at least one month (median exposure time was 1.07 years (IQR 0.28-3.0)). Patients who were carriers of the CYP2C19*2 genetic variant had 15 primary endpoint events, which was a composite of death, MI, and urgent revascularisation during treatment with clopidogrel, while non-carriers had only 11 primary endpoint events (HR 3.69 (95% CI 1.69-8.05), p=0.0005). Further, the study demonstrated that the CYP2C19*2 genetic variant "was the only independent predictor of cardiovascular events (HR 4.04 (1.81-9.02), p=0.0006)." The investigators noted that additional genetic variants, such as CYP2C19*17, may play a role in the reduced responsiveness to clopidogrel and that it remains unclear if a higher maintenance dose could overcome this reduced clopidogrel responsiveness.(Lancet by Jean-Philippe Collet, et al.)
More News: Click on one of the links below for more news
All News Articles
Acute Coronary Syndromes |
Biomarker |
Cardiovascular Imaging |
CT Surgery |
Diabetes |
Electrophysiology |
General Cardiology |
Guidelines |
Health Policy |
Heart Failure |
Hypertension |
Interventional |
Peripheral Arterial Disease |
Prevention |
Valvular Heart Disease |